LISATA THERAPEUTICS, INC. — Director's Dealing 2022

Jan 12, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2022-01-10

Reporting Person: Davidson Michael H. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-10	Common Stock	A	65430	—	Acquired	209753	Direct

Footnotes

F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023.

F2: Includes 137,207 unvested restricted stock units.